Pharmaxon

Pharmaxon (Pharmaxon) is a privately held biopharmaceutical company. It is principally engaged in the discovery and development of therapeutics for the treatment of nervous system disorders. The product portfolio of the company include: PR-21, a PSA mimotope synthetic peptide and PR-P drugs are effective against nervous system disorders, including degenerative diseases, lesions, and tumors, PR-4 to treat chronic brain and spinal cord injury, PR-10 to treat peripheral nervous system and PR-110 to treat glioblastoma. In addition, Pharmaxon focuses on the development of therapies for spinal cord injury, memory disorders, and glioblastoma. Further, the company serves neurology and neuro-oncology markets. Pharmaxon is headquartered in Marseille, France.

Street: 
Parc Scientifique de Luminy
City: 
Marseille
Postcode: 
13288
Federal State : 
France
WebSite: 
www.pharmaxon.com
Fax: 
33-491-269328

Company Index Score

Current Index Score Historical Index Score
  • Pharmaxon currently scores 50 % in the index.
  • Pharmaxon is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Pharmaxon is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets